Ebola virus disease: an update for anesthesiologists and intensivists;La maladie à virus Ebola: mise à jour pour les anesthésiologistes et intensivistes

Canadian Journal of Anesthesia

Volumn 62, Issue 1, 2015, Pages 80-91

  Funk, Duane J ^a   Kumar, Anand ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VACCINE;

AEROSOL; ANESTHESIST; ARTICLE; CLINICAL PROTOCOL; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; EARLY INTERVENTION; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; ELECTROLYTE DISTURBANCE; ENDOTRACHEAL INTUBATION; EPIDEMIC; EXPERIMENTAL THERAPY; GEOGRAPHIC DISTRIBUTION; HUMAN; INCIDENCE; INFECTION PREVENTION; INTENSIVIST; MEDICAL EDUCATION; MEDICAL PROCEDURES; MORTALITY; NONHUMAN; PATHOGENESIS; PATIENT CARE; PRIORITY JOURNAL; PROTECTIVE EQUIPMENT; RESPIRATION CONTROL; RESUSCITATION; RISK REDUCTION; THERAPY EFFECT; VACCINATION; AFRICA; ANESTHESIOLOGY; CRITICAL ILLNESS; HEALTH; HEMORRHAGIC FEVER, EBOLA; PATHOPHYSIOLOGY; PROCEDURES;

AFRICA, WESTERN; ANESTHESIOLOGY; CRITICAL ILLNESS; DISEASE OUTBREAKS; GLOBAL HEALTH; HEMORRHAGIC FEVER, EBOLA; HUMANS; PROTECTIVE DEVICES;

EID: 84922074280     PISSN: 0832610X     EISSN: 14968975     Source Type: Journal    
DOI: 10.1007/s12630-014-0257-z     Document Type: Article

References (60)

1. World Health Organization. Ebola Virus Disease in Guinea. Available from URL: http://www.who.int/csr/don/archive/disease/ebola/en/ (accessed October 2014).
2. Briand S, Bertherat E, Cox P, et al. The international Ebola emergency. N Engl J Med 2014; 371: 1180-3.
3. World Health Organization. Ebola Virus Disease Update - West Africa. Available from URL: http://www.who.int/csr/don/archive/disease/ebola/en/ (accessed October 2014).
4. Meltzer MI, Atkins CY, Santibanez S, et al. Estimating the future number of cases in the ebola epidemic – liberia and sierra leone, 2014-2015. MMWR Surveill Summ 2014; 63: 1-14.
5. Chan M. Ebola virus disease in West Africa – no early end to the outbreak. N Engl J Med 2014; 371: 1183-5.
6. Centers for Disease Control. Cases of Ebola Diagnosed in the United States. Available from URL: http://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/united-states-imported-case.html (accessed October 2014).
7. New York Times. Ebola Infects Spanish Nurse, a First in West. Available from URL: http://www.nytimes.com/2014/10/07/world/europe/spain-reports-first-case-of-ebola-contracted-outside-west-africa.html?_r=0 (accessed October 2014).
8. Martini GA. Marburg agent disease: in man. Trans R Soc Trop Med Hyg 1969; 63: 295-302.
9. Johnson KM, Lange JV, Webb PA, Murphy FA. Isolation and partial characterisation of a new virus causing acute haemorrhagic fever in Zaire. Lancet 1977; 1: 569-71.
10. Mahanty S, Bray M. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 2004; 4: 487-98.
11. Towner JS, Sealy TK, Khristova ML, et al. Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog 2008; 4: e1000212.
12. Formenty P, Hatz C, Le Guenno B, Stoll A, Rogenmoser P, Widmer A. Human infection due to Ebola virus, subtype Cote d’Ivoire: clinical and biologic presentation. J Infect Dis 1999; 179(Suppl 1): S48-53.
13. Jahrling PB, Geisbert TW, Dalgard DW, et al. Preliminary report: isolation of Ebola virus from monkeys imported to USA. Lancet 1990; 335: 502-5.
14. Baize S, Pannetier D, Oestereich L, et al. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med 2014; 371: 1418-25.
15. Sanchez A, Geisbert TW, Feldmann H. Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley PM, Griffin DE, editors. Fields Virology. Philadelphia: Lippincott Williams & Wilkins; 2006. p. 1409-48.
16. Volchkov VE, Volchkova VA, Muhlberger E, et al. Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science 2001; 291: 1965-9.
17. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet 2011; 377: 849-62.
18. Leroy EM, Kumulungui B, Pourrut X, et al. Fruit bats as reservoirs of Ebola virus. Nature 2005; 438: 575-6.
19. Morvan JM, Deubel V, Gounon P, et al. Identification of Ebola virus sequences present as RNA or DNA in organs of terrestrial small mammals of the Central African Republic. Microbes Infect 1999; 1: 1193-201.
20. Swanepoel R, Leman PA, Burt FJ, et al. Experimental inoculation of plants and animals with Ebola virus. Emerg Infect Dis 1996; 2: 321-5.
21. Bermejo M, Rodriguez-Teijeiro JD, Illera G, Barroso A, Vila C, Walsh PD. Ebola outbreak killed 5000 gorillas. Science 2006; 314: 1564.
22. Changula K, Kajihara M, Mweene AS, Takada A. Ebola and Marburg virus diseases in Africa: increased risk of outbreaks in previously unaffected areas? Microbiol Immunol 2014; 58: 483-91.
23. Zaki SR, Shieh WJ, Greer PW, et al. A novel immunohistochemical assay for the detection of Ebola virus in skin: implications for diagnosis, spread, and surveillance of Ebola hemorrhagic fever. Commission de Lutte contre les Epidémies a Kikwit. J Infect Dis 1999; 179 Suppl 1: S36-47.
24. Dowell SF, Mukunu R, Ksiazek TG, Khan AS, Rollin PE, Peters CJ. Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidémies a Kikwit. J Infect Dis 1999; 179(Suppl 1): S87-91.
25. Geisbert TW, Hensley LE, Gibb TR, Steele KE, Jaax NK, Jahrling PB. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest 2000; 80: 171-86.
26. Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, Saphire EO. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 2008; 454: 177-82.
27. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Kagan E, Hensley LE. Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 2003; 188: 1618-29.
28. Fowler RA, Fletcher T, Fischer WA 2nd, et al. Caring for Critically ill patients with ebola virus disease: perspectives from West Africa. Am J Respir Crit Carer Med 2014; 190: 733-7.
29. Villinger F, Rollin PE, Brar SS, et al. Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J Infect Dis 1999; 179(Suppl 1): S188-91.
30. Sanchez A, Lukwiya M, Bausch D, et al. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J Virol 2004; 78: 10370-7.
31. Clark DV, Jahrling PB, Lawler JV. Clinical management of filovirus-infected patients. Viruses 2012; 4: 1668-86.
32. Kortepeter MG, Bausch DG, Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis 2011; 204(Suppl 3): S810-6.
33. Hunt BJ. Bleeding and coagulopathies in critical care. N Engl J Med 2014; 370: 847-59.
34. Rollin PE, Bausch DG, Sanchez A. Blood chemistry measurements and D-Dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus. J Infect Dis 2007; 196(Suppl 2): S364-71.
35. Sadek RF, Khan AS, Stevens G, Peters CJ, Ksiazek TG. Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995: determinants of survival. J Infect Dis 1999; 179(Suppl 1): S24-7.
36. Marik PE, Cavallazzi R. Does the central venous pressure predict fluid responsiveness? An updated meta-analysis and a plea for some common sense. Crit Care Med 2013; 41: 1774-81.
37. Kumar A, Anel R, Bunnell E, et al. Pulmonary artery occlusion pressure and central venous pressure fail to predict ventricular filling volume, cardiac performance, or the response to volume infusion in normal subjects. Crit Care Med 2004; 32: 691-9.
38. Walley KR. Use of central venous oxygen saturation to guide therapy. Am J Respir Crit Care Med 2011; 184: 514-20.
39. Lamperti M, Bodenham AR, Pittiruti M, et al. International evidence-based recommendations on ultrasound-guided vascular access. Intensive Care Med 2012; 38: 1105-17.
40. Weiner MM, Geldard P, Mittnacht AJ. Ultrasound-guided vascular access: a comprehensive review. Journal of Cardiothoracic and Vascular Anesthesia 2013; 27: 345-60.
41. Kiraly LN, Differding JA, Enomoto TM, et al. Resuscitation with normal saline (NS) vs. lactated ringers (LR) modulates hypercoagulability and leads to increased blood loss in an uncontrolled hemorrhagic shock swine model. J Trauma 2006; 61: 57-64; discussion 64-5.
42. O’Malley CM, Frumento RJ, Hardy MA, et al. A randomized, double-blind comparison of lactated Ringer’s solution and 0.9% NaCl during renal transplantation. Anesth Analg 2005; 100: 1518-24.
43. Yunos NM, Bellomo R, Hegarty C, Story D, Ho L, Bailey M. Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA 2012; 308: 1566-72.
44. McCluskey SA, Karkouti K, Wijeysundera D, Minkovich L, Tait G, Beattie WS. Hyperchloremia after noncardiac surgery is independently associated with increased morbidity and mortality: a propensity-matched cohort study. Anesth Analg 2013; 117: 412-21.
45. Finfer S, Bellomo R, Boyce N, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004; 350: 2247-56.
46. Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358: 125-39.
47. Myburgh JA, Finfer S, Bellomo R, et al. Hydroxyethyl Starch or saline for fluid resuscitation in intensive care. N Engl J Med 2012; 367: 1901-11.
48. Perner A, Haase N, Guttormsen AB, et al. Hydroxyethyl starch 130/0.42 versus Ringer’s acetate in severe sepsis. N Engl J Med 2012; 367: 124-34.
49. Levi M, Schultz M, van der Poll T. Disseminated intravascular coagulation in infectious disease. Semin Thromb Hemost 2010; 36: 367-77.
50. Huggins JW. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis 1989; 11(Suppl 4): S750-61.
51. Ignatyev G, Steinkasserer A, Streltsova M, Atrasheuskaya A, Agafonov A, Lubitz W. Experimental study on the possibility of treatment of some hemorrhagic fevers. J Biotechnol 2000; 83: 67-76.
52. Choi JH, Croyle MA. Emerging targets and novel approaches to Ebola virus prophylaxis and treatment. BioDrugs 2013; 27: 565-83.
53. Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014; 514: 47-53.
54. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 2006; 145: 599-609.
55. Mupapa K, Massamba M, Kibadi K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis 1999; 179(Suppl 1): S18-23.
56. Feldmann H, Jones SM, Daddario-DiCaprio KM, et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog 2007; 3: e2.
57. Geisbert TW, Daddario-DiCaprio KM, Williams KJ, et al. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol 2008; 82: 5664-8.
58. Bukreyev A, Rollin PE, Tate MK, et al. Successful topical respiratory tract immunization of primates against Ebola virus. J Virol 2007; 81: 6379-88.
59. Geisbert TW, Daddario-Dicaprio KM, Lewis MG, et al. Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog 2008; 4: e1000225.
60. Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005; 11: 786-90.